QNRX QUOIN PHARMACEUTICALS LTD

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.

The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024.   The call will include a discussion of fourth quarter and 2023 financial results and a corporate update.  

The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).

The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link:

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit:  or  for updates.

For further information, contact:

Investor Relations

PCG Advisory

Stephanie Prince



(646) 863-6341



EN
07/03/2024

Underlying

QNRXQUOIN PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUOIN PHARMACEUTICALS LTD

 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 202...

Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome  – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data – QRX003 Pivotal Studies to Commence Enrollment in Q4 2025 – NETHERTON NOW Awareness Campaign Videos Achieve Over 1.5 Million Views in 6 Mo...

23h / 52m 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Q...

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6...

October 30, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Recruitment of Three Additional Patien...

Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ TreatmentInvestigator’s Global Assessment (IGA) Materially Improved from Baseline 4 (Severe) to 0 (Clear)Pruritus (itch) Reduced from 5 at baseline to 0, reflecting a complete absence of pru...

October 28, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designatio...

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) --  Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Desi...

October 21, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $...

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has e...

October 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch